v3.26.1
SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Intangible Asset, Finite-Lived [Line Items]    
Gross Carrying Amount $ 5,637,802 $ 6,341,228
Additions 900,000
Impairment losses (847,012) (1,603,426)
Accumulated Amortization
Net Book Value $ 4,790,790 $ 5,637,802
Patent Application Costs [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Estimated Useful Life [1]
Gross Carrying Amount $ 289,039 $ 289,039
Additions
Impairment losses (289,039)
Accumulated Amortization
Net Book Value $ 289,039
ANDA Acquisition Costs [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Estimated Useful Life Indefinite Indefinite
Gross Carrying Amount $ 5,348,763 $ 6,052,189
Additions 900,000
Impairment losses (557,973) (1,603,426)
Accumulated Amortization
Net Book Value $ 4,790,790 $ 5,348,763
[1] Patent application costs were incurred in relation to the Company’s abuse deterrent opioid technology. Amortization of the patent costs would have begun upon the issuance of marketing authorization by the FDA. During the year ended March 31, 2026, these costs were impaired in full as discussed above.